Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
13 Ottobre 2020 - 3:30PM
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the
“Company”), a clinical-stage biopharmaceutical company developing
products to improve survival and/or quality of life for patients
who have high unmet medical needs, is pleased to announce the
appointment of Michael Floyd as the Company’s Chief Operating
Officer.
Mr. Floyd is a serial entrepreneur who, over the
last 15 years, has formed and been a senior executive in several
life science organizations focused on the development of products
to treat infectious and rare diseases, as well as the development
of oncology drugs. He founded the early stage enterprise
Neurologic, that in-licensed technology from the NIH for a
diagnostic test for Alzheimer’s disease. In 2006 he served as the
CEO for the North American subsidiary of Arpida Ltd. and organized
the phase 3 program for the NDA submission of an MRSA drug. Then
after joining Gentium, SpA in 2011, he led the US efforts to
remediate the NDA for defibrotide. More recently, Mr. Floyd
co-founded Elion Oncology which licensed PCS6422 to Processa.
“Adding Mike to our leadership team will enable
me to spend more time focusing on our long-term strategic direction
and our pipeline,” said Dr. David Young, CEO and Chairman of
Processa. “Mike is a proven life science entrepreneur with a
demonstrated track record of successfully delivering results. He
has the leadership capabilities we are looking for to help us grow
Processa. In addition to assisting me in overseeing operations,
Mike will manage our public relations program and work with Patrick
Lin, our Chief Business- Strategy Officer, to ensure that our
existing investors and potential investors are informed as the
Processa drugs hit their key milestones over the next 12-18
months.”
“I am excited and delighted to join the Processa
team and to leverage the company’s incredibly talented development
team to efficiently bring important, life-changing therapies to
patients with underserved, serious indications,” Mr. Floyd said.
“As the founder of Elion, I greatly resonated with the manner in
which the Processa team operates, and I have the greatest
confidence in their disciplined approach to highly efficient
pharmaceutical development. I appreciate how Processa developed a
pipeline of de-risked drugs while planning to efficiently and
safely attack high-value milestones. Elion sought out a
collaborative engagement with the very best development partners
and we found that partner in Processa. Our oncology drug 6422 is in
great hands with Processa given their experience with this class of
oncology therapy, their experience in oncology drug development,
the Regulatory Science approach they use to develop drugs, and
their overall corporate approach to efficiently run and manage
Processa.”
About Processa Pharmaceuticals,
Inc.
The mission of Processa has been to develop
products for which existing clinical evidence of efficacy already
exists in unmet medical need conditions – medical conditions for
which patients need treatment options that will improve survival
and/or quality of life. The Company has assembled a proven
regulatory science development team, management team and board of
directors. The members of the Processa development team have been
involved with more than 30 drug approvals by the FDA (including
drug products targeted to orphan disease conditions) and 100 FDA
meetings throughout their careers.
Forward-Looking Statements
This release contains forward-looking
statements. The statements in this press release that are not
purely historical are forward-looking statements which involve
risks and uncertainties. Actual future performance outcomes and
results may differ materially from those expressed in
forward-looking statements. Please refer to the documents filed by
Processa Pharmaceuticals with the SEC, specifically the most recent
reports on Forms 10-K and 10-Q, which identify important risk
factors which could cause actual results to differ from those
contained in the forward-looking statements.
For More Information:
Michael Floydmfloyd@processapharma.com
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Lug 2023 a Lug 2024